| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$185.2M | ROE | −36.61% |
| Net Margin | — | ROIC | −40.35% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on therapies for women's cancers. Its lead candidate is palazestrant, an estrogen receptor antagonist and selective ER degrader in Phase 3 for ER-positive, HER2-negative breast cancer, including the OPERA-01 trial as monotherapy. The company is also studying palazestrant in combination with CDK4/6 and PI3Ka inhibitors in earlier-phase trials for advanced or metastatic breast cancer.
| Market Cap | $1.01B | Trading Days | 1359 |
| 52W High | 36.26 |
| 52W Low | 4.47 |
| % Off High | −67.95% |
| YTD | −53.52% | 1Y | 140.58% |
| 3Y | 38.00% | 5Y | −51.42% |
| Since incept. (ann.) | −24.01% |
| Ann. Volatility (1Y) | 161.84% | Ann. Volatility (3Y) | 113.60% |
| Sharpe (1Y) | 1.09 | Sharpe (3Y) | 0.54 |
| Max Drawdown (1Y) | −74.35% | Max Drawdown (3Y) | −82.15% |
| Beta (3Y, vs SPY) | 0.21 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | $1.03B | — |
| LBRX | LB PHARMACEUTICALS INC | $1.00B | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $1.04B | — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $990.3M | — |
| PCRX | Pacira BioSciences, Inc. | $1.05B | 167.6 |
| BIOA | BioAge Labs, Inc. | $974.4M | — |
| JBIO | Jade Biosciences, Inc. | $972.4M | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $1.06B | — |
| FBRX | Forte Biosciences, Inc. | $1.06B | — |
| ANRO | Alto Neuroscience, Inc. | $962.3M | — |
| SVRA | Savara Inc | $1.09B |
| — |
| SPTX | Seaport Therapeutics, Inc. | $1.10B | — |
